ACC CardiaCast Innovation in Action: Addressing Unmet Needs in Thrombotic Conditions
10 snips
Aug 15, 2025 
Dr. Roxana Mehran, a renowned cardiologist and clinical trial leader, joins Dr. Carolyn Lam, an esteemed academic leader in women's heart health, for a compelling discussion. They delve into the global impact of thrombotic conditions, accounting for a quarter of deaths worldwide. The pair explore current treatments, the risks of bleeding, and innovative strategies targeting factor XI to enhance patient outcomes. They also highlight the Milvexian trials and share insights on equitable access to new therapies, while encouraging young clinician-scientists to embrace mentorship.
AI Snips
Chapters
Transcript
Episode notes
Thrombosis Drives Global Mortality
- Thrombotic conditions like heart attack and stroke are major global killers, causing tissue death when clots form inappropriately.
- Roxana Mehran emphasizes these clot-driven events drive substantial morbidity and mortality worldwide.
Bleeding Limits Antithrombotic Therapy
- Current anticoagulants reduce clots but increase bleeding, which remains a major clinical problem.
- Carolyn Lam notes newer DOACs lowered bleeding versus warfarin but did not eliminate significant bleeding risk.
Factor XI: A Precision Target
- Targeting specific coagulation factors may prevent thrombosis while preserving normal hemostasis.
- Roxana Mehran highlights factor XI as a promising target to reduce pathologic clots without blocking necessary bleeding control.